Although VaxGen Inc. will complete enrollment of 5,400 volunteers this month in the North American Phase III trial of its AIDSVax vaccine to prevent HIV infection, the final results are not scheduled for three years, making the study something of a living time capsule.

However, VXGN (Brisbane, Calif.) will not have to wait quite that long for a look at the effects of its HIV gp120 vaccine.